ArticleMedical oncology (Northwood, London, England)2011
Potential role of serum level of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Digging into the Solubility Factor in Cancer Diagnosis: A Case of Soluble CD44 Protein.Biosensors · 2025Review
- CD44: a cancer stem cell marker and therapeutic target in leukemia treatment.Frontiers in immunology · 2024Review
- Activation of Interferon Signaling in Chronic Lymphocytic Leukemia Cells Contributes to Apoptosis Resistance via a JAK-Src/STAT3/Mcl-1 Signaling Pathway.Biomedicines · 2021Article
- C-C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation.Hematology (Amsterdam, Netherlands) · 2016Article
- Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.Haematologica · 2016Article
- The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer.BMC cancer · 2015Article
- The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.Haematologica · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence indicates that the slowly expanding population of B cells that characterizes chronic lymphocytic leukemia (CLL) results primarily from defects in responses to cytokines. We evaluated the prognostic value of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia (B-CLL) and analyzed their source and regulation secretion in B-CLL clones in vitro. Levels of soluble CD44 standard (sCD44s) and IFN-γ were analyzed by enzyme-linked immunosorbent assay. B-CLL cells were separated and stimulated in vitro for the detection of both markers. Serum levels of sCD44s and IFN-γ were significantly elevated in patients with B-CLL in comparison with normal persons. Elevated levels of sCD44s and IFN-γ were associated with an advanced disease as reflected by increased values as stage progress. In B-CLL, sCD44s as well as IFN-γ was shed from leukemia cells as shown by in vitro cultures. Stimulation of B-CLL clones results in a proliferation-associated increased secretion of sCD44s and IFN-γ. B-CLL clones from advanced-stage patients are characterized by an increased capacity for proliferation and production of both markers in comparison with early-stage patients. Our present results suggest that sCD44 and IFN-γ may be of major importance in the pathogenesis of B-CLL, and inhibition of the effects of sCD44 and IFN-γ could be a potential therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.